Mar 2021 $80 M No. 9 $50 to $250 million 41
Aura Biosciences, Inc.: Raise no. 9, Mar 2021 × Investors in this round 41 investors had bought by the notice of Apr 6, 2021: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $80 M of $80 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.D. · Executive Officer, Director Julie Feder · Executive Officer David Johnson · Director Giovanni Mariggi, Ph.D. · Director Karan Takhar · Director Raj Parekh, Ph.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Julie Feder, Secretary/CFO. Source: SEC Form D, newest notice filed Apr 6, 2021. Read the notice at the SEC .
equity SEC Jun 2020 $10 M No. 8 $10 to $50 million 32
Aura Biosciences, Inc.: Raise no. 8, Jun 2020 × Investors in this round 32 investors had bought by the notice of Jul 9, 2020: 32 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $17 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.D. · Executive Officer, Director Julie Feder · Executive Officer Art Pappas · Director Casper Breum · Director Christian Schetter · Director George Golumbeski, Ph.D. · Director Giovanni Mariggi, Ph.D. · Director Joel Jean-Mairet, Ph.D. · Director Raj Parekh, Ph.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Julie Feder, Secretary/CFO. Source: SEC Form D, newest notice filed Jul 9, 2020. Read the notice at the SEC .
equity SEC Apr 2019 $20 M No. 7 $10 to $50 million 36
Aura Biosciences, Inc.: Raise no. 7, Apr 2019 × Investors in this round 36 investors had bought by the notice of Apr 12, 2019: 36 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $20 M of $40 M offered; $20 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.D. · Executive Officer, Director Julie E. Feder · Executive Officer Lewis E. Geffen · Executive Officer Alan E. Walts, Ph.D. · Director Art E. Pappas · Director Casper E. Breum · Director Giovanni E. Mariggi, Ph.D. · Director Joel E. Jean-Mairet, Ph.D. · Director Mark E. Chin · Director Raj E. Parekh, Ph.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Elisabet de los Pinos, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 12, 2019. Read the notice at the SEC .
equity SEC Dec 2017 $42 M No. 6 $10 to $50 million 42
Aura Biosciences, Inc.: Raise no. 6, Dec 2017 × Investors in this round 42 investors had bought by the notice of Dec 13, 2018: 42 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $42 M of $42 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.D. · Executive Officer, Director Julie E. Feder · Executive Officer Lewis E. Geffen · Executive Officer Alan E. Walts, Ph.D. · Director Art E. Pappas · Director Casper E. Breum · Director Dale E. Pfost, Ph.D. · Director Joel E. Jean-Mairet, Ph.D. · Director Mark E. Chin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Elisabet de los Pinos, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 13, 2018. Read the notice at the SEC .
equity SEC Sep 2016 $12 M No. 5 $10 to $50 million 38
Aura Biosciences, Inc.: Raise no. 5, Sep 2016 × Investors in this round 38 investors had bought by the notice of Nov 2, 2017: 38 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $12 M of $12 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.D. · Executive Officer, Director Lewis E. Geffen · Executive Officer Michael E. Wyzga · Executive Officer Alan E. Walts, Ph.D. · Director Art E. Pappas · Director Dale E. Pfost, Ph.D. · Director Joel E. Jean-Mairet, Ph.D. · Director Jose' E. Baselga, Ph.D. · Director Peter E. Wirth · Director Raj E. Parekh, Ph.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Elisabet de los Pinos, Ph.D., Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 2, 2017. Read the notice at the SEC .
debt, options SEC Feb 2015 $21 M No. 4 $10 to $50 million 21
Aura Biosciences, Inc.: Raise no. 4, Feb 2015 × Investors in this round 21 investors had bought by the notice of Mar 5, 2015: 21 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $21 M of $35 M offered; $13 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $1,212,500 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.D. · Executive Officer, Director Peter B. Finn · Executive Officer · Secretary Alan Walts, Ph.D. · Director · Executive Chairman of Board of Directors. Art Pappas · Director Dale Pfost, Ph.D. · Director Javier Garcia · Director Joel Jean-Mairet, Ph.D. · Director Jose Baselga, Ph.D. · Director Peter Wirth · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Of the total amount sold, $6,753,833.62 has been paid to the Company. The balance will be paid upon the happening of certain events.”On the use of proceeds: “Executive Salaries and Director Compensation”Signed by Peter B. Finn, Secretary. Source: SEC Form D, newest notice filed Mar 5, 2015. Read the notice at the SEC .
equity, options SEC Apr 2014 $4 M No. 3 $2 to $10 million 41
Aura Biosciences, Inc.: Raise no. 3, Apr 2014 × Investors in this round 41 investors had bought by the notice of Aug 14, 2014: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken $25,000
What was sold equity Exemption claimed Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $500,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.d. · Executive Officer, Director · President and Treasurer Peter B. Finn · Executive Officer · Secretary Alan Walts · Director Israel Ruiz · Director Javier Garcia · Director Jose Baselga, Ph.d. · Director Peter B. Wirth · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Executive Salaries”Signed by Peter B. Finn, Secretary. Source: SEC Form D, newest notice filed Aug 14, 2014. Read the notice at the SEC .
equity SEC Aug 2012 $3 M No. 2 $2 to $10 million 22
Aura Biosciences, Inc.: Raise no. 2, Aug 2012 × Investors in this round 22 investors had bought by the notice of Dec 26, 2012: 22 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $5,000
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $500,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.D. · Executive Officer, Director Peter B. Finn · Executive Officer Israel B. Ruiz · Director Jose Baselga, Ph.D. · Director Pedro Granadillo · Director Salvador B. Garcia-Atance · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Salaries”Signed by Peter B. Finn, Secretary and General Counsel. Source: SEC Form D, newest notice filed Dec 26, 2012. Read the notice at the SEC .
equity SEC May 2011 $3 M No. 1 $2 to $10 million 23
Aura Biosciences, Inc.: Raise no. 1, May 2011 × Investors in this round 23 investors had bought by the notice of Aug 26, 2011: 23 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $25,000
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $500,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Elisabet de los Pinos, Ph.D. · Executive Officer, Director Peter C. Finn · Executive Officer Edmundo Muniz, M.D., Ph.D. · Director Lawrence C. Best · Director Pedro Granadillo · Director Salvador C. Garcia-Atance · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “salaries”Signed by Peter B. Finn, Esq., Secretary and General Counsel. Source: SEC Form D, newest notice filed Aug 26, 2011. Read the notice at the SEC .
equity SEC